Hillstream BioPharma, Inc. (HILS)

NASDAQ: HILS · IEX Real-Time Price · USD
0.400
0.00 (-0.05%)
At close: Nov 25, 2022 4:00 PM
0.420
+0.020 (4.87%)
After-hours: Nov 25, 2022 4:00 PM EST
-0.05%
Market Cap 4.62M
Revenue (ttm) n/a
Net Income (ttm) -4.25M
Shares Out 11.53M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,558
Open 0.401
Previous Close 0.401
Day's Range 0.4 - 0.405
52-Week Range 0.37 - 4.24
Beta n/a
Analysts Buy
Price Target 6.12 (+1,428.5%)
Earnings Date Nov 17, 2022

About HILS

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3... [Read more]

Industry Biotechnology
IPO Date Jan 12, 2022
Employees 1
Stock Exchange NASDAQ
Ticker Symbol HILS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for HILS stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 1,428.47% from the latest price.

Price Target
$6.12
(1,428.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ...

4 days ago - GlobeNewsWire

Hillstream's New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing a...

Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growth Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growth

1 month ago - GlobeNewsWire

Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences

BRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ...

1 month ago - GlobeNewsWire

Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20

BRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting...

2 months ago - GlobeNewsWire

Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ...

4 months ago - GlobeNewsWire

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors

4 months ago - GlobeNewsWire

Why Hillstream BioPharma Shares Are Trading Higher Today?

Hillstream BioPharma Inc (NASDAQ: HILS) shares are trading higher after it authorized a share repurchase program to acquire up to $1 million in common stock.  As of March 31, Hillstream had approximatel...

5 months ago - Benzinga

Hillstream BioPharma Provides Corporate Update

BRIDGEWATER, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream,” the “Company”), a biotechnology company developing novel therapeutic candidates targeting fe...

5 months ago - GlobeNewsWire

Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022

BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ: HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting f...

6 months ago - GlobeNewsWire

Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting D...

BRIDGEWATER, NJ, March 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ: HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting f...

8 months ago - GlobeNewsWire

Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma

- Uveal melanoma is a n aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease -

9 months ago - GlobeNewsWire

Hillstream BioPharma Provides Business Review with Key Pipeline Updates

Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review No...

9 months ago - Accesswire

SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14...

R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments BRI...

9 months ago - Accesswire

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatr...

BRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferrop...

9 months ago - Accesswire

Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR...

Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in Ferroptosis...

9 months ago - Accesswire

Hillstream BioPharma Announces Closing of Initial Public Offering

BRIDGEWATER, NJ / ACCESSWIRE / January 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferrop...

10 months ago - Accesswire